



**Corp. Off.:-** 201, "The Summit Business Bay"  
Behind Guru Nanak Petrol Pump,  
Off Andheri Kurla Road, Andheri (E),  
Mumbai - 400 093 (India)  
Ph. : +91 22 69073100

14<sup>th</sup> July, 2021

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

Stock Symbol-533543  
Through : BSE Listing Centre

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

Scrip Code- BROOKS  
Through : NEAPS

Dear Sir/Madam,

**Sub: Press Release**

Please find attached press release issued by the Company titled:

"Brooks announces new investments in their joint venture to build an integrated global carbapenem business".

Thanking You,


Yours faithfully

For **BROOKS LABORATORIES LIMITED**

(Jyoti Sancheti)

**Company Secretary and Compliance Officer**

**Membership No. F9639**



## **Brooks announces new investments in their joint venture to build an integrated global carbapenem business**

**Vadodara, India, July 14, 2021 – Brooks Laboratories Limited** (BSE:533543, NSE: BROOKS), a leading pharmaceutical company, today announced that it has entered into a new agreement with SteriScience Specialities Private Limited (SteriScience) to make fresh investments in its subsidiary **Brooks SteriScience Limited (BSL)** to expand manufacturing infrastructure and integrated capabilities for their carbapenem business.

Last year, Brooks had entered into a collaboration with SteriScience to carry out manufacturing, marketing and distribution of carbapenems for the global market with an integrated infrastructure to manufacture both drug substances and drug products. As part of this collaboration, Brooks and SteriScience had setup BSL, a joint venture company engaged in the manufacturing of the carbapenem products which also housed the manufacturing facility at Vadodara, India.

SteriScience has already invested Rs. 40.0 Crores into BSL, and as per the new agreement signed, SteriScience will infuse an additional amount of Rs. 74.5 Crores, making a total investment commitment of Rs. 114.5 Crores in BSL. The new investments will be deployed to set up a dedicated Ertapenem formulation facility and integrate the APIs for all the four carbapenems under development. Besides this, BSL will also set up front-end capabilities to market carbapenem products globally, including the US, Europe, Canada, Australia and India. BSL has already filed its first ANDA in addition to dossier submissions for 30+ European countries. Going forward Brooks SteriScience Ltd. (the current manufacturing JV) will be the only effective JV and SteriBrooks Penems Private Limited (the Marketing JV), will be merged or dissolved as per legal advice in due course. All IPs / ANDAs / Dossiers will be owned by BSL across the world.

**Atul Ranchal, Chairman of Brooks, commented:** "Globally, Carbapenems are a \$2 billion plus opportunity with limited players having dedicated capabilities to manufacture these products for the regulated markets. These fresh investments will bolster our global positioning and fast-track our ability to penetrate new markets with a significant competitive advantage driven by manufacturing, quality and supply assurance."

**Rajesh Mahajan, Managing Director of Brooks, said:** "We are very pleased with this deal and are excited to partner in this JV. We believe that this deal will further build upon our manufacturing strengths to continue our journey to deliver high quality, niche and specialized products globally."

After completing new investments of Rs. 74.5 Crores, SteriScience will have 51% of BSL, while Brooks will have the remaining 49% ownership.

### **About Brooks**

Brooks Laboratories Limited was incorporated on January 23, 2002 to manufacture pharmaceutical products. The Company, today, manufactures a wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets amongst others. The Company operates two manufacturing facilities in Baddi, Himachal Pradesh and Vadodara, Gujarat. In 2020, SteriScience, entered into a Joint Venture with Brooks Laboratories Limited for building a robust carbapenem business with integrated manufacturing capabilities. The transaction with Brooks was approved by the shareholders of Brooks. For more details please visit [www.brookslabs.net](http://www.brookslabs.net)